Integra Q1 revenue rises 2.4% to $391.9 million; adjusted EPS guidance raised
Integra LifeSciences reported first-quarter 2026 revenue of $391.9 million, up 2.4% from a year earlier, and a narrower GAAP net loss of $4.6 million. It raised its full-year 2026 adjusted earnings per share guidance to $2.40 to $2.50 from $2.30 to $2.40 and reaffirmed its revenue outlook of $1.662 billion to $1.702 billion. Free cash flow was negative $5.0 million in the quarter and net debt was $1.6 billion, figures shareholders may weigh alongside the improved profit measures.
Key points
- First-quarter revenue was $391.9 million, up 2.4% reported and 1.3% organic, versus the prior year
- GAAP net loss narrowed to $(0.06) per diluted share from $(0.33); adjusted EPS rose to $0.54 from $0.41
- Full-year adjusted EPS guidance raised to $2.40 to $2.50; revenue guidance reaffirmed at $1.662 billion to $1.702 billion
- Operating cash flow was $9.8 million; net debt at quarter end was $1.6 billion and total leverage ratio was 4.1x
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.